C3J was founded by Wenyuan Shi, Ph.D., out of UCLA’s School of Dentistry to explore the potential of C16G2 for Dental Caries. C3J has advanced this lead molecule into Phase 2 clinical trials, along with a diagnostic test for Streptococcus mutans.  With the addition of the synthetic phage platform, C3J is expanding the pipeline with synthetic phage for oral pathogens.

 

Discovery Preclinical Phase 1 Phase 2 Phase 3
Targeted Antimicrobials C16G2 STAMP: Prevention of Dental Caries
Synthetic Phage for Oral Pathogens
Discovery Verification Validation Commercial
PCR Diagnostic Test Streptococcus mutans

See our Medical Pipeline